Spondyloarthritis & psoriatic arthritis
Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study
Main finding · Composite CVD (co-primary)Result — go to the resultHazard ratio 1.17Authors' conclusion
We did not find significant differences in the risks of CVD and GIB between celecoxib and nsNSAIDs in AS patients.
Study context
- Population
- Adult ankylosing spondylitis (AS) patients newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days, 2013–2017, Korean Health Insurance Review and Assessment database3,164 celecoxib, 18,924 nsNSAID before matching
- Participants
- 3,047 vs 3,047
- Exposure
- Celecoxib vs non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs)
- Celecoxibn = 3,047
- nsNSAIDsn = 3,047reference
- Outcome
- Co-primary: composite CVD events (hospitalization for MI, ischaemic heart disease, stroke, transient ischaemic attack, HF, coronary revascularization) and composite GIB (hospitalization for upper and lower GIB)
Methodological detailsnationwide, propensity-score matched (1:1)
- Nationwide
- Propensity-score matched (1:1)
Main finding
Composite CVD (co-primary)
Hazard ratio
1.17
P = 0.499
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Co-primary: composite GIB · propensity-score matched
HR 0.87 · P = 0.696
Each component of composite cardiovascular disease (CVD) and gastrointestinal bleeding (GIB)
- No significant differences between the two groups
Original publication
Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study. Scand J Rheumatol. Published 3 March 2025. doi:10. 1080/ 03009742. 2025. 2467556
Composed by AI from the published abstract and checked against it. How Briefs are made →